Oakland‑based Albert Invent closed a $55 million Series B round led by TCV, aiming to expand its Valence model, which claims to be about 45 times more accurate for chemical‑industry applications.
Oakland‑based Albert Invent has closed a $55 million Series B financing round, led by TCV, to accelerate the rollout of its chemistry‑focused artificial intelligence platform.
Funding round details
The round, which values Albert Invent at $340 million post‑money, brings the total capital raised by the startup to over $80 million. Existing investors also participated, underscoring confidence in the company’s Valence model.
Valence model performance
Albert Invent’s Valence model claims to be roughly 45 times more accurate than traditional computational chemistry methods when applied to chemical‑industry use cases, promising faster drug discovery and materials design.
The platform leverages deep learning architectures trained on proprietary datasets, enabling it to predict molecular properties and reaction outcomes with reduced experimental cycles.
Strategic use of funds
The new capital will be allocated to scaling the engineering team, expanding cloud infrastructure, and forging partnerships with pharmaceutical and specialty‑chemical firms seeking AI‑driven R&D solutions.
- Hire additional AI researchers and data scientists
- Enhance the Valence model’s training pipeline
- Broaden go‑to‑market efforts in the US and Europe
Albert Invent also plans to deepen collaborations with academic institutions to stay at the forefront of AI‑enabled chemistry research.
For readers interested in broader AI developments, see the AI coverage on uxc.news.
Source: AI Weekly coverage of Albert Invent’s $55 million Series B